Melanie Ivarsson
Corporate Officer/Principal en MODERNA, INC. .
Perfil
Melanie Ivarsson is currently the Director at Loqus23 Therapeutics Ltd.
and the Chief Development Officer at Moderna, Inc. Previously, she worked as the Vice President & Head-Global Clinical Operations at Takeda Pharmaceuticals U.S.A., Inc. Dr. Ivarsson holds a doctorate from the University of Bristol and an MBA from MIT Sloan School of Management.
Cargos activos de Melanie Ivarsson
Empresas | Cargo | Inicio |
---|---|---|
MODERNA, INC. | Corporate Officer/Principal | 30/01/2020 |
Loqus23 Therapeutics Ltd.
Loqus23 Therapeutics Ltd. BiotechnologyHealth Technology Loqus23 Therapeutics Ltd.engages in research and development of biotechnology. The company was founded on March 29, 2019 and is headquartered in in Reading, the United Kingdom. | Director/Board Member | 25/01/2022 |
Antiguos cargos conocidos de Melanie Ivarsson.
Empresas | Cargo | Fin |
---|---|---|
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | - |
Formación de Melanie Ivarsson.
University of Bristol | Doctorate Degree |
MIT Sloan School of Management | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
MODERNA, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |
Loqus23 Therapeutics Ltd.
Loqus23 Therapeutics Ltd. BiotechnologyHealth Technology Loqus23 Therapeutics Ltd.engages in research and development of biotechnology. The company was founded on March 29, 2019 and is headquartered in in Reading, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Melanie Ivarsson